Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.59 |
| ▸ | ECE1 | P42892 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 3/20 | 0.59 |
| ▸ | CASP1 | P29466 | 8/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.52 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7155003 | 1.00 | MME (0.59) | MMEECE1CTSKCASP1CAPN1 | |
| SCHEMBL4430771 | 1.00 | MME (0.59) | MMEECE1CTSKCASP1CAPN1 | |
| SCHEMBL29453232 | 0.99 | MME (0.58) | MMEECE1CTSKCASP1CAPN1 | |
| SCHEMBL10868042 | 0.91 | CAPN1 (0.58) | MMEECE1CTSKCASP1CAPN1 | |
| SCHEMBL30902886 | 0.91 | CTSK (0.58) | MMEECE1CTSKCASP1CAPN1 | |
| SCHEMBL30902885 | 0.91 | CTSK (0.58) | MMEECE1CTSKCASP1CAPN1 | |
| SCHEMBL3140616 | 0.91 | CASP3 (0.62) | MMEECE1CTSKCASP1CASP3 | |
| SCHEMBL614741 | 0.91 | CASP3 (0.62) | MMEECE1CTSKCASP1CASP3 | |
| SCHEMBL28645697 | 0.90 | CTSK (0.57) | CTSKCASP1PSMB8PSMB9PSMB5 | |
| SCHEMBL28645693 | 0.90 | MME (0.60) | MMEECE1CTSKCAPN1PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196859-A1 | Novel antibacterial agents | ENGASE, PEPD, PGLS | MME 186/4885ECE1 438/4885CTSK 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.